ClinicalTrials.gov
public full text
Public Domain
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease#1295112
- Tricaprilin in Mild to Moderate Alzheimer's Disease#848470
- Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease#905509
- A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers#1162915
- A Taxonomy of Mental Health and Technology Needs for Alzheimer's and Dementia Caregivers#287164
Record · ID 1228116
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive